Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ascendis Pharma A (ASND) Total Liabilities: 2012-2025

Historic Total Liabilities for Ascendis Pharma A (ASND) over the last 12 years, with Sep 2025 value amounting to $1.6 billion.

  • Ascendis Pharma A's Total Liabilities rose 18.76% to $1.6 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $5.6 billion, marking a year-over-year increase of 21.37%. This contributed to the annual value of $1.4 billion for FY2024, which is 33.11% up from last year.
  • As of Q3 2025, Ascendis Pharma A's Total Liabilities stood at $1.6 billion, which was up 7.60% from $1.4 billion recorded in Q2 2025.
  • Ascendis Pharma A's 5-year Total Liabilities high stood at $1.6 billion for Q3 2025, and its period low was $196.0 million during Q1 2021.
  • Moreover, its 3-year median value for Total Liabilities was $1.2 billion (2024), whereas its average is $1.2 billion.
  • Data for Ascendis Pharma A's Total Liabilities shows a peak YoY surged of 303.36% (in 2022) over the last 5 years.
  • Quarterly analysis of 5 years shows Ascendis Pharma A's Total Liabilities stood at $230.3 million in 2021, then skyrocketed by 266.15% to $843.1 million in 2022, then rose by 23.95% to $1.0 billion in 2023, then soared by 31.42% to $1.4 billion in 2024, then rose by 18.76% to $1.6 billion in 2025.
  • Its Total Liabilities stands at $1.6 billion for Q3 2025, versus $1.4 billion for Q2 2025 and $1.3 billion for Q1 2025.